Singapore markets open in 3 hours 6 minutes

Nuvation Bio Inc. (NUVB)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
5.71+0.10 (+1.78%)
At close: 04:00PM EST
5.71 0.00 (0.00%)
After hours: 04:31PM EST

Nuvation Bio Inc.

1500 Broadway
Suite 1401
New York, NY 10036
United States
332 208 6102

Full-time employees58

Key executives

NameTitlePayExercisedYear born
Dr. David T. Hung M.D.Founder, Pres, CEO & Director1.16MN/A1958
Ms. Jennifer A. FoxChief Financial Officer557.9kN/A1972
Dr. Gary Hattersley Ph.D.Chief Scientific Officer687.88kN/A1967
Ms. Stacy MarkelSr. VP of HRN/AN/A1965
Dr. Sergey YurasovChief Medical OfficerN/AN/A1969
Dr. Lisa V. DeLuca B.S., M.S., Ph.D.Sr. VP of Regulatory AffairsN/AN/AN/A
Dr. David C. Hanley Ph.D.Chief Technical Operations OfficerN/AN/A1970
Kenneth GuernseySec.N/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting CDK2, CDK4, and CDK6. It is also developing NUV-868, a selective inhibitor of the BET family of epigenetic transcriptional regulators; NUV-569, a differentiated selective inhibitor of the Wee1 kinase; NUV-1182, an adenosine receptor inhibitor; and DDC platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to androgen receptor-expressing cancer cells , as well as PARP inhibitor to ER-expressing cancer cells. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was incorporated in 2018 and is headquartered in New York, New York.

Corporate governance

Nuvation Bio Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.